Navigation Links
Programming cells to home to specific tissues may enable more effective cell-based therapies
Date:10/27/2011

Boston, MA - Stem cell therapies hold enormous potential to address some of the most tragic illnesses, diseases, and tissue defects world-wide. However, the inability to target cells to tissues of interest poses a significant barrier to effective cell therapy. To address this hurdle, researchers at Brigham and Women's Hospital (BWH) have developed a platform approach to chemically incorporate homing receptors onto the surface of cells. This simple approach has the potential to improve the efficacy of many types of cell therapies by increasing the concentrations of cells at target locations in the body. These findings are published online in the journal Blood on Oct. 27, 2011.

For this new platform, researchers engineered the surface of cells to include receptors that act as a homing device. "The central hypothesis of our work is that the ability of cells to home to specific tissues can be enhanced, without otherwise altering cell function," said corresponding author Jeffrey M. Karp, PhD, co-director of the Regenerative Therapeutics Center at BWH and a principal faculty member of the Harvard Stem Cell Institute. "By knowing the 'zip code' of the blood vessels in specific tissues, we can program the 'address' onto the surface of the cells to potentially target them with high efficiencies."

While conventional cell therapies that include local administration of cells can be useful, they are typically more invasive with limited potential for multiple doses. "You can imagine, that when the targeted tissue is cardiac muscle, for example to treat heart attacks or heart failure, injecting the cells directly into the heart can be an invasive procedure and typically this approach can only be performed once," said Dr. Karp, also an assistant professor at Harvard Medical School and affiliate faculty Harvard-MIT Division of Health Sciences and Technology.

Using the platform the researchers created, the cells are prepared to travel directly to the area of interest after being injected through a common and much less invasive intravenous infusion method. "These engineered cells may also be more effective because multiple doses can be administered" stated Debanjan Sarkar, PhD, previously a postdoctoral fellow in Dr. Karp's lab and now an Assistant Professor of Biomedical Engineering at the State University of New York, University at Buffalo.

"The necessity for a more effective delivery approach stems from the potential diseases cell therapy may address," said Dr. Karp, noting that the approach can be used to systemically target bone producing cells to the bone marrow to treat osteoporosis, cardiomyocytes to the heart to treat ischemic tissue, neural stem cells to the brain to treat parkinson's disease, or endothelial progenitor cells to sites of peripheral vascular disease to promote formation of new blood vessels.

The researchers concluded that, as the understanding of the mechanisms of cell trafficking grows, the ability to improve homing to specific tissues through engineered approaches should significantly enhance cell therapy by reducing the invasiveness of local administration, permitting repeat dosing, and potentially reducing the number of cells required to achieve a therapeutic effect, ultimately providing better outcomes for patients.
'/>"/>

Contact: Holly Brown-Ayers
hbrown-ayers@partners.org
617-534-1603
Brigham and Women's Hospital
Source:Eurekalert  

Related medicine news :

1. OASIS Recognized for Brain Fitness Programming
2. Adritech Software Releases Website Realizer, a Website Builder to Create Websites without Any Programming Knowledge
3. University of Michigan Health System earns major grant to expand childhood obesity programming
4. Fetal programming of disease risk to next generation depends on parental gender
5. New Study Uses Adult Stem Cells in Effort to Save Limbs of Patients with Peripheral Arterial Disease
6. New study suggests stem cells sabotage their own DNA to produce new tissues
7. Attacking cancer cells with hydrogel nanoparticles
8. UCR researcher identifies mechanism malaria parasite uses to spread in red blood cells
9. Pittsburgh Neurosurgeons Explore Use of Drug that Illuminates Brain Tumor Cells To Guide Surgery
10. New tool illuminates connections between stem cells and cancer
11. Bitter melon extract attacks breast cancer cells
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Programming cells to home to specific tissues may enable more effective cell-based therapies
(Date:12/5/2016)... ... December 05, 2016 , ... The new knee compression sleeves ... to buy neoprene knee sleeves for lifting and any sport that requires ... on two main aspects to provide a higher quality knee sleeve performance. Firstly it ...
(Date:12/5/2016)... , ... December 05, 2016 , ... ... today that they have teamed up with The American College of Surgeons (ACS) ... ACS’s Committee on Trauma, the “Bleeding Control Basic” course is a pilot program ...
(Date:12/4/2016)... ... December 03, 2016 , ... ... and many more tools allowing FCPX editors to create professional looking video in ... , Perfect Harmony contains a beautifully designed 3D environment for placing in ...
(Date:12/4/2016)... ... December 04, 2016 , ... "Pro3rd Displace ... animation styles with unique displacement design elements," said Christina Austin - CEO of ... Choose from a variety of design styles that include both left aligned and ...
(Date:12/2/2016)... ... 2016 , ... Halfway through its partnership with First 5 LA, Western University ... than 15,900 children 5 years old and younger and treatment services to more than ... of five years to Western University of Health Sciences, UCLA and USC, beginning March ...
Breaking Medicine News(10 mins):
(Date:12/5/2016)... , December 5, 2016 PharmaBoardroom today releases ... . ... This report offers companies, investors, policymakers, and stakeholders crucial insight ... of Europe , home to some of the world,s ... pharmaceutical companies in Novartis and Roche, and with a number one ranking ...
(Date:12/5/2016)... VIENNA and TAIPEI, Taiwan , ... 12 months of treatment ropeginterferon alfa-2b showed non-inferiority to hydroxyurea ... demonstrated a significantly better safety and tolerability profile of ropeginterferon ... data from PROUD-PV and the ongoing long-term follow-up trial CONTINUATION-PV ... PharmaEssentia intends to present this data to the ...
(Date:12/4/2016)... ORLEANS , Dec. 2, 2016  Former Attorney General ... Jr., Esq. , a partner at the law firm of ... commenced an investigation into Lannett Company, Inc. (NYSE: ... Bloomberg published an article titled "U.S. Charges in Generic-Drug ... "antitrust investigation by the Justice Department, begun about two years ...
Breaking Medicine Technology: